NCT03062046View on ClinicalTrials.gov

Evaluation of Ablation Index and VISITAG™ (ABI-173)

NACompletedINTERVENTIONAL

Enrollment

340

Participants

Timeline

Start Date

January 27, 2017

Primary Completion Date

March 27, 2019

Study Completion Date

March 27, 2019

Conditions

Paroxysmal Atrial Fibrillation

Interventions

DEVICE

RF ablation

RF ablation

Trial Locations (17)

Unknown

LKH Univ. Klinikum Graz, Graz

OLV Aalst, Aalst

AZ Sint-Jan, Bruges

ZOL Genk, Genk

Jessa Ziekenhuis, Hasselt

Aarhus Universitetshospital Skejby, Aarhus

Gentofte Hospital, Gentofte Municipality

Odense University Hospital, Odense

Clinique Clairval Marseille, Marseille

Clinique Pasteur, Toulouse

Mater Private Heart & Vascular Centre, Dublin

Ospedaliera Universitaria Pisana, Pisa

Policlinico Caisilino Roma, Rome

Medisch Spectrum Twente, Enschede

Herzzentrum, Luzerner Kantonsspital, Lucerne

Liverpool Heart and Chest Hospital, Liverpool

St. Thomas' Hospital, London

All Listed Sponsors

lead

Biosense Webster, Inc.

INDUSTRY

NCT03062046 - Evaluation of Ablation Index and VISITAG™ (ABI-173) | Biotech Hunter | Biotech Hunter